블로그

• Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer patients with hormone-receptor positive/HER2-negative metastatic breast cancer is CDK4/6 inhibitor plus Methods This real-world cohort study is based on electronic health records from Capital Region of Denmark blog.naver.com · 2025.07.08